撰文丨王聪 编辑丨王多鱼 排版丨水成文 细菌和古菌进化出了多种多样的防御机制来抵御病毒 （噬菌体） 的侵害。例如在 细菌和古菌中广泛存在的 CRISPR-Cas 系统，对该系统的研究不仅揭示了基本 的生物学过程，还带来了革命性的新技术，让基因编辑、表达调控和 RNA 敲低成为可能。 许多最近发现的细菌防御机制，尤其是那些与膜相关的防御机制，我们仍知之甚少， Kiwa 系统 就是其中一个例子。 Kiwa 系统是 已测序细菌基因组中 20 个最 丰富的防御系统之一，这表明其防御谱广泛且进化成功。其由两种蛋白成分组成：四通跨膜蛋白 KwaA 和 KwaB，然而， Kiwa 系统 是如何感知噬菌体并提供保 护的，目前仍不清楚。 2025 年 7 月 28 日 ，纪念斯隆凯特琳癌症中心 张志莹 博士、 南安普顿大学 吴仪 博士等作为共同第一作者， 在国际顶尖学术期刊 Cell 上发表了题为： Kiwa is a membrane-embedded defence supercomplex activated at phage attachment sites 的研究论文。 该研究解析了细菌的一种跨膜防御机制—— Kiw ...

Core Viewpoint - The report published in The Lancet highlights the urgent need for comprehensive strategies to prevent and treat hepatocellular carcinoma (HCC), predicting a doubling of global cases by 2025 if no action is taken [2][6]. Group 1: Current Situation and Statistics - HCC is the sixth most common cancer globally and the third leading cause of cancer-related deaths, with 870,000 new cases and 760,000 deaths reported in 2022. Projections indicate that by 2050, new cases could rise to 1.52 million, and deaths could reach 1.37 million [8]. - The report indicates that over 70% of HCC patients are diagnosed at an advanced stage, resulting in a 5-year survival rate of only 5%-30% [13]. Group 2: Causes and Trends - By 2050, hepatitis B virus (HBV) will remain the primary cause of HCC, but its proportion is expected to decrease from 39.0% in 2022 to 36.9%. Conversely, alcohol-related HCC cases are projected to increase from 18.8% to 21.1%, and cases related to metabolic dysfunction-associated fatty liver disease (MASH) are expected to rise from 8% to 10.8% [10][11]. Group 3: Prevention and Early Detection - The report emphasizes that over 60% of HCC cases are preventable through the control of HBV, HCV, alcohol consumption, and fatty liver disease. For instance, in 2022, more than 540,000 of the 870,000 new cases were avoidable [15]. - Early screening can triple survival rates, as demonstrated in Japan, where 68% of HCC cases are detected at an early stage, leading to an 80% 5-year survival rate [17]. Group 4: Recommendations and Strategies - The committee has outlined ten actionable recommendations, including strengthening viral hepatitis prevention, reducing alcohol consumption, and improving early detection of HCC [19]. - Specific strategies include universal HBV vaccination, government-led measures to reduce alcohol consumption, and tailored national strategies to address the rising incidence of MASH [20]. Group 5: Stakeholder Involvement - The report stresses that reducing the global burden of HCC will require collaborative efforts from policymakers, healthcare providers, international organizations, researchers, and patient advocacy groups [21].

Core Viewpoint - A new wearable all-in-one obstructive sleep apnea management system has been developed, integrating flexible piezoelectric monitoring and soft magnetoelastic stimulation, addressing the limitations of traditional polysomnography (PSG) in cardiovascular parameter monitoring [4][11]. Group 1: Research Development - The research was a collaboration between Southwest Jiaotong University, City University of Hong Kong, and West China Hospital of Sichuan University [2]. - The developed system features a customized piezoelectric composite sensor for continuous physiological signal monitoring and a soft magnetoelastic actuator for non-invasive mechanical stimulation [7][11]. - The system utilizes a machine learning algorithm to achieve a 92.7% accuracy rate in real-time detection of sleep apnea events [8]. Group 2: Clinical Validation - Rigorous laboratory and clinical studies demonstrated that the developed apnea management system (AMS) is comparable to the clinical gold standard, PSG, in identifying apnea events [9]. - Parallel comparison signals from AMS and PSG confirmed the effectiveness of feedback stimulation [11]. Group 3: System Features and Benefits - The AMS integrates continuous physiological monitoring and non-invasive mechanical stimulation, providing a closed-loop system for sleep apnea management [11]. - This system not only addresses the limitations of traditional PSG in tracking cardiovascular responses but also offers a scalable and user-friendly platform for personalized sleep health care at home [11][12].

Core Viewpoint - The research highlights the role of RNA-binding protein RRP1 in regulating inflammation through its interaction with RNA, specifically in the context of one-carbon metabolism, providing new therapeutic targets for diseases like rheumatoid arthritis [3][10]. Group 1: Role of RBP in Inflammation - RNA-binding proteins (RBP) are crucial in the initiation and resolution of inflammation, and understanding their interaction with RNA and metabolism may offer new targets for controlling inflammation [5]. - RBP's interaction with RNA is dynamic and essential for maintaining cellular homeostasis, with dysregulation potentially leading to disease [3]. Group 2: Research Findings - The study published by the team led by Academician Cao Xuetao identified RRP1 as a suppressor of macrophage inflammation by regulating thymidylate synthase (Tyms) mRNA, affecting its transport and translation efficiency [3][10]. - RRP1 was found to inhibit one-carbon metabolism, thereby suppressing inflammatory responses in macrophages, which could provide a new strategy for treating autoimmune diseases [10]. Group 3: Mechanistic Insights - Mechanistically, RRP1 binds to the Tyms transcript and post-transcriptionally reduces TYMS protein levels, leading to the inhibition of folate metabolism and one-carbon metabolism-driven inflammation [7][10]. - Myeloid-specific RRP1-deficient mice exhibited severe experimental arthritis, with increased pro-inflammatory cytokines and immune damage, indicating the importance of RRP1 in inflammation regulation [8]. Group 4: Clinical Relevance - In rheumatoid arthritis patients, the expression of RRP1 in peripheral blood mononuclear cells was negatively correlated with TYMS expression and serum IL-1β levels, suggesting a potential biomarker role for RRP1 in inflammatory diseases [8].

Core Viewpoint - The study reveals that hypoxia inhibits ferroptosis through a HIF-independent mechanism by suppressing KDM6A, a key player in lipid metabolism and ferroptosis resistance [2][5]. Group 1: Mechanism of Ferroptosis Regulation - Long-term hypoxia can inhibit ferroptosis in a HIF-independent manner [5]. - Hypoxia suppresses KDM6A, reshaping the lipid profile to confer resistance to ferroptosis [3][5]. - KDM6A acts as a non-classical oxygen sensor in the ferroptosis process, indicating a novel regulatory pathway [2][5]. Group 2: Implications for Cancer - The loss of KDM6A, a tumor suppressor, is commonly observed in bladder cancer, leading to resistance to ferroptosis [5]. - Pharmacological inhibition of EZH2, which opposes KDM6A activity, restores sensitivity to ferroptosis in bladder tumors carrying KDM6A mutations [4][5].

Core Viewpoint - The article discusses the significant impact of mosquitoes on global health, particularly in relation to malaria transmission and the innovative genetic research aimed at combating this issue through gene editing technology [2][3][4]. Group 1: Malaria and Mosquito Impact - In 2023, approximately 263 million people were infected with malaria, resulting in nearly 600,000 deaths, with 80% of these fatalities being children [2]. - Efforts to control malaria transmission have stagnated due to mosquitoes developing resistance to insecticides and the malaria-causing parasites becoming resistant to treatments like artemisinin [3]. Group 2: Genetic Research and Innovations - A study published in Nature by researchers from UC San Diego and Johns Hopkins University utilized CRISPR-Cas9 technology to edit the FREP1 gene in the major malaria vector, Anopheles stephensi, to block the transmission of malaria parasites [4][6]. - The specific genetic modification involved changing one amino acid from L224 to Q224 in the FREP1 gene, which effectively prevents malaria parasites from entering the mosquito's salivary glands without affecting the mosquito's normal growth and reproduction [6][8]. Group 3: Gene Drive System - The research team developed a linked allele drive system to ensure the rapid spread of the FREP1 Q224 allele within mosquito populations, achieving an increase from 25% to 93% frequency in just 10 generations [9]. - This innovative approach leverages a naturally occurring mosquito allele, providing a powerful barrier against multiple malaria parasites and potentially applicable to various mosquito species and populations [10].

Core Insights - The article discusses the significant differences in phenotypic traits between modern humans and their close relatives, such as gorillas, primarily attributed to the expansion of the neocortex and increased complexity of neuronal connections [1][3] - It highlights the role of specific gene expansions unique to humans that contribute to brain evolution, particularly focusing on the GPR89B and FRMPD2B genes [3][10] Gene Expansion and Brain Evolution - A study published in the journal Cell identifies human-specific gene expansions that contribute to brain evolution, with GPR89B promoting brain volume expansion and FRMPD2B regulating synaptic signaling complexity [2][3][7] - The research utilized the T2T-CHM13 genome, which successfully assembled previously unsequenced regions of the human genome, including critical areas like telomeres and centromeres [5][10] Identification of Unique Gene Families - The research team identified 213 human-specific gene families and 362 paralogous genes that are primary candidates for shaping universal human brain characteristics [6][10] - Among these, 1,002 paralogous genes were identified in the T2T-CHM13 genome, with 148 gene families potentially driving human brain evolution [10]

Core Viewpoint - Immune checkpoint blockade therapy has significantly changed the landscape of cancer treatment, showing strong efficacy in various cancer types, but the reasons for differential responses among patients remain unclear [1][3]. Group 1: Research Findings - A recent study published in Nature reveals that autoantibodies (AAb), typically associated with autoimmune diseases, can influence the response of cancer patients to immune checkpoint blockade therapy [3][5]. - The research involved 374 cancer patients receiving immune checkpoint blockade therapy and 131 healthy controls, mapping the immune response to 6172 extracellular and secreted proteins [5]. - The study identified approximately 3000 unique autoantibody responses in cancer patients, indicating a diverse "autoantibody response group" that has not yet reached saturation [7]. Group 2: Clinical Implications - Patients with interferon-targeting antibodies have a 40-fold higher probability of responding to treatment, contrasting with COVID-19, where similar antibodies increase mortality risk by 20-200 times [7]. - The findings suggest that targeting the exoproteome with specific autoantibodies could enhance the efficacy of immune checkpoint blockade therapy, leading to the potential development of drugs that mimic beneficial autoantibodies or neutralize harmful ones [9]. - The study also highlights that anti-TL1A antibodies enhance treatment effects by preventing T-cell apoptosis in the tumor microenvironment [12]. Group 3: Future Directions - The research opens new avenues for optimizing cancer immunotherapy by leveraging the role of autoantibodies in treatment responses, providing new targets and strategies for improving patient outcomes [9].

Core Viewpoint - GLP-1 receptor agonists and co-agonists, initially developed for type 2 diabetes treatment, have expanded benefits including weight loss and reduced incidence of chronic diseases such as cardiovascular disease, chronic kidney disease, and metabolic dysfunction-related fatty liver disease [2][3][27]. Summary by Sections GLP-1 Class Drugs Overview - GLP-1 drugs like liraglutide, dulaglutide, semaglutide, and tirzepatide enhance insulin secretion, reduce glucagon secretion, and slow gastric emptying, contributing to weight loss and appetite suppression [2]. - These drugs have been approved for treating type 2 diabetes and obesity, with additional benefits in reducing chronic kidney disease, myocardial infarction, stroke, and cardiovascular mortality [2]. Clinical Evidence and Expanding Benefits - Daniel J. Drucker's article highlights the benefits of GLP-1 drugs beyond diabetes and obesity, including cardiovascular disease, chronic kidney disease, metabolic dysfunction-related fatty liver disease, osteoarthritis, obstructive sleep apnea, and peripheral artery disease [3]. Cardiovascular and Kidney Disease - Semaglutide received FDA approval in 2024 as the first weight loss drug proven to reduce major adverse cardiovascular events in adults with obesity or overweight and established cardiovascular disease [7]. - In clinical trials, semaglutide significantly reduced the incidence of non-fatal myocardial infarction and stroke, with a risk ratio of 0.8 compared to placebo [7]. - In patients with heart failure with preserved ejection fraction (HFpEF), semaglutide improved symptoms and reduced cardiovascular death and heart failure-related events by 31% [10]. Metabolic Dysfunction-Related Fatty Liver Disease - In a clinical trial involving 1,200 adults with metabolic dysfunction-associated steatotic liver disease (MASH), semaglutide improved liver histology and increased the rate of fatty liver resolution [13]. - The benefits of semaglutide may be secondary to weight loss or improvements in liver metabolism and inflammation [13]. Osteoarthritis - The STEP 9 trial showed that semaglutide treatment significantly reduced pain scores in patients with knee osteoarthritis and resulted in greater weight loss compared to placebo [17]. Obstructive Sleep Apnea - The SURMOUNT-OSA trial demonstrated that tirzepatide significantly reduced the apnea-hypopnea index in adults with moderate to severe obstructive sleep apnea [19]. Peripheral Artery Disease - The STRIDE trial indicated that semaglutide improved walking distance in patients with peripheral artery disease, correlating with weight loss [21]. Neuroprotective Effects - GLP-1 drugs have been associated with reduced stroke incidence and may lower the risk of all-cause dementia, including Alzheimer's disease [23]. - Ongoing trials are exploring the potential of oral semaglutide in modifying Alzheimer's disease [23]. Mechanisms of Action - The exact mechanisms by which GLP-1 drugs provide benefits independent of weight loss remain unclear, but they may involve improvements in insulin sensitivity and inflammation reduction [25][26]. - GLP-1 drugs consistently lower inflammatory biomarkers, suggesting immune-modulating effects that may contribute to their therapeutic benefits [26]. Conclusion and Future Directions - The broad benefits of GLP-1 drugs extend to various chronic conditions, with ongoing research exploring their applications in substance abuse, mental health, and neurodegenerative diseases [27]. - Understanding the dose-response relationship and optimal treatment duration for conditions beyond diabetes and obesity may open new therapeutic avenues for GLP-1 drugs [27].

Core Viewpoint - The article highlights significant research published in the journal Cell, with a focus on groundbreaking studies from Chinese scholars in various fields, including Alzheimer's disease treatment, cartilage regeneration, and innovative RNA-protein interaction technologies [2]. Group 1: Alzheimer's Disease Research - A study by researchers from Gladstone Institutes and UCSF identified two FDA-approved cancer drugs, letrozole and irinotecan, that can reverse gene expression changes associated with Alzheimer's disease, significantly improving memory and reducing pathological features in a mouse model [4][7]. Group 2: Cartilage Regeneration - Research from Tongji University and Hainan Medical University discovered Procr+ chondroprogenitors that are sensitive to mechanical stimuli, crucial for maintaining cartilage homeostasis and promoting regeneration after joint injury, indicating potential for treating knee diseases like osteoarthritis [9][12]. Group 3: Prime Editing for Neurological Disorders - The Broad Institute's study demonstrated the use of prime editing technology in mice to correct common ATP1A3 gene mutations associated with alternating hemiplegia of childhood, leading to significant improvements in clinical symptoms and lifespan [14][17]. Group 4: RNA-Protein Interaction Technology - A new RNA-binding protein identification technique called SPIDR was developed, allowing for the analysis of multiple RNA-binding proteins' binding sites, which could enhance understanding of RNA biology and mechanisms of translational suppression under cell stress [19][21]. Group 5: Post-Stroke Brain Inflammation - Research from Johns Hopkins University revealed that the mast cell receptor Mrgprb2/MRGPRX2 mediates brain inflammation after a stroke, and inhibiting this receptor can reduce inflammation and improve neurological outcomes in mice [23][25]. Group 6: Aging Proteome Atlas - A comprehensive study by the Chinese Academy of Sciences constructed a proteome aging atlas across a 50-year lifespan, identifying aging trajectories and key proteins like GAS6 that drive vascular and systemic aging [27].